Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

1.04
+0.05005.05%
Post-market: 1.060.0157+1.51%17:41 EST
Volume:41.77K
Turnover:42.17K
Market Cap:3.41M
PE:-0.08
High:1.06
Open:0.9900
Low:0.9600
Close:0.9900
52wk High:20.40
52wk Low:0.9532
Shares:3.28M
Float Shares:2.42M
Volume Ratio:0.55
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.8100
EPS(LYR):-30.9580
ROE:-27725.96%
ROA:-31.66%
PB:-1.62
PE(LYR):-0.03

Loading ...

HCW Biologics files to sell 3.4M shares of common stock for holders

TIPRANKS
·
Jan 10

HCW Biologics Raises $3.8 Million Through Warrant Exercise and Equity Issuance

Reuters
·
Jan 01

HCW Biologics Secures $4M Through Warrant Exercise

TIPRANKS
·
Nov 21, 2025

HCW Biologics Raises $4 Million Through Private Placement of Unregistered Warrants

Reuters
·
Nov 21, 2025

BRIEF-Hcw Biologics Announces Warrant Inducement Agreement

Reuters
·
Nov 19, 2025

HCW Biologics Inc - Announces Warrant Inducement Agreement

THOMSON REUTERS
·
Nov 19, 2025

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire
·
Nov 19, 2025

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

GlobeNewswire
·
Nov 18, 2025

HCW Biologics Q3 EPS $(2.02) Misses $1.58 Estimate, Sales $15.606M Beat $7.000M Estimate

Benzinga
·
Nov 15, 2025

HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040

Reuters
·
Nov 10, 2025

HCW Biologics announces data presented for TCE Program based on TRBC platform

TIPRANKS
·
Nov 07, 2025

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

GlobeNewswire
·
Nov 07, 2025

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment

GlobeNewswire
·
Oct 22, 2025

HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire
·
Oct 16, 2025

HCW Biologics Granted Nasdaq Extension to Regain Compliance with Listing Rules

Reuters
·
Oct 16, 2025

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

GlobeNewswire
·
Sep 30, 2025

Press Release: HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

Dow Jones
·
Sep 18, 2025

HCW Biologics’ Innovative Lead Candidate HCW11-040 Boosts Cancer Therapy Potential

TIPRANKS
·
Sep 18, 2025

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

GlobeNewswire
·
Sep 16, 2025

Consumer Sentiment, Oil Inventory Reports Set for Release as US Futures Little Changed in Friday's Premarket Session

MT Newswires Live
·
Sep 12, 2025